ClinicalTrials.gg
Not yet recruitingNCT07762963CORE-TRUpdated Sep 25, 2026

Turkish Validation of the Core Life Activities Scale

An observational study in Life Style, Healthy, sponsored by Tokat Gaziosmanpasa University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Tokat Gaziosmanpasa University · Observational

Updated Sep 25, 2026Start date movedGo to Updates ↓
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to adapt the Core Life Activities Scale (CORE) into Turkish and evaluate its validity and reliability in Turkish-speaking adults. The CORE is a five-item self-report scale that assesses five basic areas of daily life: eating, sleeping, physical activity, learning new things, and social relationships. Approximately 300 adults aged 18 years and older will participate in the study. Participants will complete the Turkish version of the CORE together with measures of health-related quality of life. The CORE will also be administered again one week later to evaluate test-retest reliability. The findings will determine whether the Turkish version of the CORE is a valid and reliable tool for assessing core life activities in Turkish-speaking adults.

Read the detailed description

his observational methodological study will evaluate the validity and reliability of the Turkish version of the Core Life Activities Scale (CORE). The study will include approximately 300 Turkish-speaking adults aged 18 years and older from different age groups and socioeconomic backgrounds.

The CORE is a five-item self-report measure designed to assess five core areas of daily life: eating habits, sleep, physical activity, learning new things, and social relationships. Each item is rated on a five-point Likert scale ranging from 1 (never) to 5 (always).

After providing informed consent, participants will complete a demographic information form, the Turkish version of the CORE, the 12-Item Short Form Health Survey (SF-12), and the World Health Organization Quality of Life-BREF (WHOQOL-BREF). The SF-12 and WHOQOL-BREF will be used to examine the validity of the Turkish CORE. The CORE will be administered again one week later to assess test-retest reliability.

Psychometric analyses will be performed to evaluate the reliability and validity of the Turkish version of the CORE. Internal consistency, test-retest reliability, and construct-related validity will be examined. Data collection is planned between August 20, 2026 and September 30, 2026.

02

Conditions studied

  • Life Style, Healthy

Browse trials for

Keywords

  • Validity
  • Reliability
  • Activities of Daily Living
  • Physical Activity
03

In context

Motor Activity

9,798 studies on the registry are indexed under Motor Activity; 1,910 are open to participants now.

This study's planned enrollment of 300 is above the median of 98 across 1,235 observational studies indexed under Motor Activity.

Browse Motor Activity studies →

Lead sponsor

Tokat Gaziosmanpasa University is the lead sponsor of 170 studies on the registry; 38 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will consist of approximately 300 Turkish-speaking adults aged 18 years and older from different age groups and socioeconomic backgrounds. Participants who meet the eligibility criteria and voluntarily agree to participate will be included in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adults aged 18 years or older. Ability to read and understand Turkish fluently. No cognitive or physical impairment that would prevent completion of the questionnaires.

Willingness to participate voluntarily and provide .

Exclusion criteria

Exclusion Criteria:

Diagnosis of a severe psychiatric or neurological disorder such as schizophrenia, bipolar disorder, or dementia.

Presence of a terminal or severe medical condition that substantially affects activities of daily living, such as advanced-stage cancer or severe cardiovascular disease.

Language barriers that prevent adequate understanding of the questionnaires. Providing inconsistent, intentionally inaccurate, or implausibly rapid questionnaire responses.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Turkish-Speaking Adults

    Approximately 300 Turkish-speaking adults aged 18 years and older will be included in this observational validation study. Participants will complete the Turkish version of the Core Life Activities Scale (CORE), the SF-12, and the WHOQOL-BREF. The CORE will be administered again one week later to assess test-retest reliability. No intervention will be administered.

06

What researchers measure

Primary outcomes

  1. Internal Consistency of the Turkish Core Life Activities Scale

    Internal consistency of the Turkish version of the Core Life Activities Scale (CORE) will be evaluated using Cronbach's alpha coefficient. The CORE consists of five items assessing eating, sleeping, physical activity, learning new things, and social relationships, with each item rated on a 5-point Likert scale from 1 (never) to 5 (always).

    Time frame: Baseline

  2. Test-Retest Reliability of the Turkish Core Life Activities Scale

    Test-retest reliability of the Turkish version of the CORE will be evaluated by comparing CORE scores obtained at the initial assessment with scores obtained one week later. The association between the two assessments will be examined to determine the temporal stability of the scale.

    Time frame: Baseline and 1 week

  3. Construct Validity of the Turkish Core Life Activities Scale

    Construct validity of the Turkish version of the CORE will be evaluated by examining its relationships with health-related quality of life measures assessed using the 12-Item Short Form Health Survey (SF-12) and the World Health Organization Quality of Life-BREF (WHOQOL-BREF).

    Time frame: Baseline

Secondary outcomes

  1. Factor Structure of the Turkish Core Life Activities Scale

    The factor structure of the Turkish version of the CORE will be examined using factor analysis to evaluate its underlying dimensional structure.

    Time frame: Baseline

07

Study locations

1 site
08

References and documents

Publications

  • Cho S, Park K, Jung D, Son G, Cho E, Choi KH. Development and validation of the core life activities scale. Front Psychol. 2024 Apr 22;15:1359276. doi: 10.3389/fpsyg.2024.1359276. eCollection 2024. PubMed 38711750 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2026, 0 months later.

Of 490 non-industry observational studies under Motor Activity, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 48. This study's planned 0 months is below that.

Counting every sponsor, half of 500 studies reached it within 22 months; a quarter within 8 and three quarters within 48.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Sep 25, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2026
First posted
Aug 13, 2026
StartEst.
Sep 20, 2026was Aug 2026
Primary completionEst.
Sep 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 20, 2026→Sep 20, 2026
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Start date Aug 20, 2026→Sep 20, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07762963
Responsible party
Uğur Sözlü (associate professor, Tokat Gaziosmanpasa University) — Principal investigator
First posted
Aug 13, 2026
Start date
Sep 20, 2026 (estimated)
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Sep 25, 2026

Study contacts

Uğur Sözlü, PhD
Contact
ugur.sozlu@gop.edu.tr
05368921936
Uğur Sözlü, PhD
principal investigator · Tokat Gaziosmanpaşa Üniversitesi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion